title: Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration.
abstract: The pharmacokinetics of orally administered mefloquine were determined in six healthy male subjects and in six ulcer patients before and after a 3-day course of cimetidine (400 mg morning and evening). Peak plasma concentrations Cmax and AUC0-infinity were similarly and significantly (P < 0.05) increased after cimetidine pretreatement in both healthy subjects and peptic ulcer patients Cmax was increased by 42.4% and 20.5% while AUC0-infinity was increased by 37.5% in healthy and peptic ulcer subjects respectively. The values of t1/2ab absorption and t1/2 beta elimination, total crearance CLT/F and volume of distribution were altered to varying levels after cimetidine treatment but the changes were not statistically significant in both healthy and peptic ulcer subjects. The established long t1/2 beta and this apparent interaction between mefloquine and cimetidine which resulted in increased mefloquine plasma concentration might be of clinical significant in patients with neurological/psychiatric history.
authors: Department of Pharmaceutical Chemistry, University of Jos, Jos, Nigeria.
authors: J A
authors: JA
authors: Kolawole
authors: A
authors: A
authors: Mustapha
authors: I
authors: I
authors: Abudu-Aguye
authors: N
authors: N
authors: Ochekpe
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000962:Antimalarials / Q000493:pharmacokinetics*; D002927:Cimetidine / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D015767:Mefloquine / Q000493:pharmacokinetics*; D010437:Peptic Ulcer / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000897:Anti-Ulcer Agents; D000962:Antimalarials; D002927:Cimetidine; D015767:Mefloquine